BerGenBio's Promising Phase 1b Trial for NSCLC Patients
BerGenBio ASA, a pioneering biopharmaceutical firm focused on developing selective AXL kinase inhibitors, recently revealed encouraging preliminary safety data from their Phase 1b trial concerning the treatment of Non-Small Cell Lung Cancer (NSCLC). This innovative study evaluated the safety profile of their leading candidate, bemcentinib, in patients facing severe unmet medical needs.
Understanding The Phase 1b Study
The Phase 1b arm of the BGBC016 study aimed to assess three escalating doses of bemcentinib, cleverly combined with standard chemo-immunotherapy (CIT). This combination included doublet chemotherapy and pembrolizumab, a known immune checkpoint inhibitor marketed under the name Keytruda. The primary focus was to gauge the safety of this combination therapy administered to first-line advanced and metastatic NSCLC patients.
Key Findings From The Trial
The results from the trial have been quite promising. Key highlights include:
- All three doses chosen for the study successfully demonstrated their tolerability, with no new safety signals detected. This significant finding supports the continued clinical development of bemcentinib alongside CIT in treating NSCLC patients.
- Throughout the observation period, no dose-related effects on electrocardiographic changes (QTc), which are often a concern with tyrosine kinase inhibitors, were recorded for bemcentinib.
- Pharmacokinetic assessments confirmed that bemcentinib achieved adequate plasma exposure levels, consistent with results seen in previous studies involving patients who responded positively to pembrolizumab in second-line settings.
Insights from the CEO
Martin Olin, the Chief Executive Officer of BerGenBio, expressed optimism regarding these results. He stated, "The data show that bemcentinib has a manageable safety profile and gives us increased confidence in continuing the BGBC016 clinical trial. We are currently enrolling patients in Phase 2a, targeting those with STK11 gene mutations. We eagerly anticipate sharing more preliminary data as our research progresses."
Addressing The Need For Targeted Therapies
Patients diagnosed with STK11 mutated NSCLC generally exhibit a significantly poorer response to existing therapies compared to those with non-mutated STK11. This heightened challenge underscores the critical need for innovative treatments aimed specifically at AXL pathways, which hold promise in halting cancer growth and prolonging survival. Bemcentinib's selective inhibition of AXL may enhance responses to therapies like immune checkpoint inhibitors, based on preclinical evidence.
BerGenBio: Leading the Way
BerGenBio is committed to developing groundbreaking therapies that target AXL, positioning these drugs as potential cornerstone treatments for aggressive diseases like cancer and severe respiratory infections. With bemcentinib at the helm, the company strives to deliver transformative results for patients who previously faced limited options.
Based in Bergen, Norway, with a subsidiary in the UK, BerGenBio ASA (listed on the Oslo Stock Exchange under the ticker BGBIO) continues to push the boundaries of what's possible in biopharmaceutical development.
Frequently Asked Questions
What is the significance of the Phase 1b trial for NSCLC?
The Phase 1b trial is crucial as it evaluates the safety of bemcentinib combined with standard therapies, offering hope for better treatment options for NSCLC patients.
What are the results of the trial?
Key findings indicate that all doses were well tolerated, with no new safety signals and adequate plasma exposure levels achieved.
How does bemcentinib work?
Bemcentinib selectively inhibits AXL, which may enhance the efficacy of immune checkpoint inhibitors, particularly in patients with STK11 mutations.
What are STK11 mutations, and why are they problematic?
STK11 mutations can lead to poorer responses to existing therapies in NSCLC patients, making targeted treatments essential.
Where is BerGenBio headquartered?
BerGenBio is headquartered in Bergen, Norway, with an additional subsidiary located in Oxford, UK.
